Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NovaBay Pharmaceuticals (NBY) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to -$0.23.

  • NovaBay Pharmaceuticals' EPS (Basic) rose 9072.58% to -$0.23 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.25, marking a year-over-year increase of 10354.0%. This contributed to the annual value of -$2.53 for FY2024, which is 9817.83% up from last year.
  • As of Q3 2025, NovaBay Pharmaceuticals' EPS (Basic) stood at -$0.23, which was up 9072.58% from -$0.36 recorded in Q4 2024.
  • NovaBay Pharmaceuticals' 5-year EPS (Basic) high stood at -$0.04 for Q1 2021, and its period low was -$59.56 during Q4 2023.
  • Over the past 5 years, NovaBay Pharmaceuticals' median EPS (Basic) value was -$1.37 (recorded in 2024), while the average stood at -$9.61.
  • Its EPS (Basic) has fluctuated over the past 5 years, first tumbled by 712000.0% in 2022, then skyrocketed by 9940.08% in 2024.
  • Quarter analysis of 5 years shows NovaBay Pharmaceuticals' EPS (Basic) stood at -$0.72 in 2021, then plummeted by 611.74% to -$5.1 in 2022, then crashed by 1068.55% to -$59.56 in 2023, then surged by 99.4% to -$0.36 in 2024, then soared by 35.55% to -$0.23 in 2025.
  • Its EPS (Basic) stands at -$0.23 for Q3 2025, versus -$0.36 for Q4 2024 and -$2.48 for Q3 2024.